Targeting Buche-Inflammatory Pathway By Sk0506 To Manage Type 2 Diabetes And Alzheimer Disease

Publisher:
Springer/Plenum Publishers
Publication Type:
Journal Article
Citation:
Neurochemical Research, 2009, 34 (12), pp. 2163 - 2169
Issue Date:
2009-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2009002397OK.pdf302.86 kB
Adobe PDF
Type 2 diabetes mellitus (T2DM) and Alzheimers disease (AD) affect a large percent of the population worldwide. Experimental studies have revealed that T2DM and AD share several molecular processes that underlie their respective degenerative pathology. Based on this information, we quantified TNF-?, IL-6 levels, serum glucose, serum triglyceride, hepatic triglyceride, serum AST, serum ALT and butyrylcholinesterase (BuChE) in various rat tissues. HFD was fed to rats resulting in increased body weight, fasting blood glucose, IL-6, TNF-? levels, hepatic triglyceride, serum AST, serum ALT and BuChE. SK0506 treatment significantly prevented weight gain induced by HFD feeding. SK0506, but not Rosiglitazone, significantly reduced serum and hepatic triglycerides levels. Treatment with SK0506 also ameliorated elevated levels of both inflammatory markers (TNF-? and IL-6) and serum liver enzymes (ALT and AST) significantly in HFD fed rats. BuChE activity also reduced in skeletal muscle and adipose tissues of rats treated by SK0506. In conclusion, current study has opened new potential avenues towards research for management of T2DM and AD by Chinese herbal extracts, SK0506.
Please use this identifier to cite or link to this item: